New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 18, 2014
19:04 EDTMNOVMedicNova announces positive interim results of MN-166 phase 2a study
MediciNova announced positive interim results of a phase 2a clinical trial of MN-166 in opioid dependence. The study is being conducted at Columbia University and the New York State Psychiatric Institute and led by Dr. Sandra Comer, Professor of Neurobiology. The interim analysis was performed after the first seven patients had completed the study, which required a 6-week stay on the inpatient unit. MN-166 demonstrated a number of beneficial effects on the subjective, analgesic, and reinforcing effects of oxycodone. MN-166 significantly decreased the craving for heroin, cocaine, and tobacco. MN-166 also decreased the positive subjective effects of oxycodone measured by mean responses to statements such as "I Feel High" and "I Liked the Dose." MN-166 also enhanced the analgesic effects of oxycodone. MN-166 reduced the sum score on the McGill Pain Questionnaire, reduced the mean rating on the Painful scale, and reduced the mean rating on the Bothersome scale. Finally, MN-166 decreased the reinforcing effects of oxycodone.
News For MNOV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 23, 2014
19:04 EDTMNOVMediciNova says CDC supports recruitment for clinical trial of MN-166
Subscribe for More Information
October 22, 2014
19:01 EDTMNOVMediciNova confirmsFDA granted orphan drug designation to MN-001
Subscribe for More Information
07:28 EDTMNOVNortheast Amyotrophic Lateral Sclerosis Consortium to hold annual meeting
Subscribe for More Information
October 21, 2014
18:05 EDTMNOVMediciNova granted orphan status for idiopathic pulmonary fibrosis drug
The FDA posted on its website that MediciNova has been granted orphan status for its treatment of idiopathic pulmonary fibrosis. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use